<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1362">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913454</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00989</org_study_id>
    <nct_id>NCT04913454</nct_id>
  </id_info>
  <brief_title>CLearing Alzheimer's Disease Molecular Pathology Without Medications</brief_title>
  <acronym>CLAMP</acronym>
  <official_title>CLearing Alzheimer's Disease Molecular Pathology Without Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the most popular pathophysiological models of Alzheimer's disease, the amyloid&#xD;
      hypothesis, amyloid deposition is the causative event triggering a chain of other downstream&#xD;
      events which finally lead to Alzheimer's disease and dementia. In mouse models of Alzheimer's&#xD;
      disease, 40 Hz multi-sensory (auditory and visual) stimulation was able to reduce the number&#xD;
      and size of amyloid plaques throughout cortex and improve cognitive performance.&#xD;
&#xD;
      The primary objective of this study is to assess whether an intervention consisting of 40 Hz&#xD;
      multi-sensory (auditory and visual) stimulation is able to reduce the amyloid load in&#xD;
      non-demented amyloid-positive individuals.&#xD;
&#xD;
      As secondary objectives, the investigators will assess whether such intervention is able to:&#xD;
&#xD;
        -  improve the brain electrical activity,&#xD;
&#xD;
        -  improve or slow down the worsening of Alzheimer's blood-based biomarkers,&#xD;
&#xD;
        -  improve or slow down the worsening of cognition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in amyloid load</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in amyloid load assessed by longitudinal amyloid-PET</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in brain electrical activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in brain electrical activity (e.g. gamma power spectral density) assessed by longitudinal EEG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Alzheimer's blood-based biomarkers</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in Alzheimer's blood-based biomarkers (e.g. plasma Aβ42/Aβ40 ratio, Aβ42, Aβ40, p-tau, and neurofilament light) assessed by longitudinal blood sample collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in cognition (using the Preclinical Alzheimer Cognitive Composite (PACC) score) assessed by longitudinal neuropsychological assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Amyloid Plaque</condition>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>40 Hz multi-sensory (auditory + visual) stimulation and cognitive training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive training only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cognitive training only (1 hour per day, per 5 days/week, for a total of 8 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>40 Hz multi-sensory (auditory + visual) stimulation and cognitive training</intervention_name>
    <description>40 Hz multi-sensory (auditory + visual) stimulation and cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)</description>
    <arm_group_label>40 Hz multi-sensory (auditory + visual) stimulation and cognitive training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive training</intervention_name>
    <description>Cognitive training (1 hour/day, per 5 days/week, for a total of 8 weeks)</description>
    <arm_group_label>Cognitive training only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature (Appendix Informed Consent Form),&#xD;
&#xD;
          -  age 40-80,&#xD;
&#xD;
          -  ≥5 years of education,&#xD;
&#xD;
          -  previous evidence of brain amyloidosis (assessed by PET, CSF, or blood-based&#xD;
             biomarkers).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of epilepsy;&#xD;
&#xD;
          -  clinically relevant visual or auditory diseases/deficits;&#xD;
&#xD;
          -  clinical diagnosis of dementia;&#xD;
&#xD;
          -  contraindication to amyloid-PET;&#xD;
&#xD;
          -  inability to undergo the procedures of the study, e.g. severe behavioral disturbances;&#xD;
&#xD;
          -  severe diseases:&#xD;
&#xD;
               1. Malignant neoplasm within 5 years,&#xD;
&#xD;
               2. Life threatening diseases,&#xD;
&#xD;
               3. Severe systemic diseases (e.g. kidney insufficiency, cardiac insufficiency,&#xD;
                  decompensated diabetes, decompensated metabolic diseases, decompensated&#xD;
                  hypothyroidism, uncontrolled autoimmune diseases);&#xD;
&#xD;
          -  the participation to a clinical trial involving potential Alzheimer's disease&#xD;
             modifying therapies;&#xD;
&#xD;
          -  documented pregnancy or intention to become pregnant during the course of the study or&#xD;
             breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Daniele Altomare</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

